DIA/FDA Oligonucleotide-Based Therapeutics Conference

This event brings together leading experts from industry and regulatory bodies to inform, educate and share advancements in oligonucleotide based therapeutic product development. This year’s conference will cover optimization strategies for drug design, manufacturing, delivery and clinical testing through three tracks dedicated to covering relevant topics.

The objectives of this conference are to:

• Analyze the latest delivery strategies for clinical use of oligonucleotide therapies
• Discuss the non-clinical toxicology profile of oligonucleotide therapies and the latest improvements in predicting effects in humans
• Describe the chemistry, manufacturing and controls challenges associated with the development of oligonucleotides
• Explain the latest global regulatory updates
• Evaluate the best mechanism of interaction with patients and partner organizations to address critical needs in the rare disease community

For more information, including details of the program committee, a full agenda and registration, visit the DIA global website.